Jubilant Life Sciences has received final USFDA approval for the generic version of its non-steroidal anti-inflammatory drug, Indocin. The approval for Indomethacin capsules is a generic equivalent of Indocin of Iroko. The drug will be multiple strengths of 25 mg and 50 mg and is used in the treatment of moderate to severe inflammation and reduce pain. This is the seventh approval the company have received from the US FDA during the current financial year.
Company Profile : Jubilant Life Sciences Ltd
Leave a Reply